Life science consulting is a specialized branch of management consulting that helps pharmaceutical, biotech, medical device, and healthcare companies solve complex business and scientific problems. These firms guide clients through everything from getting a new drug approved to pricing it, launching it commercially, and acquiring other companies to strengthen their product portfolios. It sits at the intersection of deep scientific knowledge and business strategy, which is what distinguishes it from general management consulting.
What Life Science Consultants Actually Do
At its core, life science consulting is about helping companies in heavily regulated industries make better decisions. A biotech startup with a promising cancer therapy might need help designing a regulatory strategy to get approval from the FDA. A large pharmaceutical company might want to know whether acquiring a smaller competitor is worth the price. A medical device maker might need a plan to launch a new product across multiple countries, each with different reimbursement rules.
The work spans the entire product lifecycle. Early on, consultants help companies evaluate which drug candidates in their pipeline deserve continued investment. During development, they advise on clinical trial design and regulatory submissions. As a product nears approval, the focus shifts to pricing, market access, and commercial launch planning. After launch, consultants may help with lifecycle management, competitive positioning, or expansion into new markets. The thread connecting all of this is that life science companies operate under uniquely strict regulatory requirements, and the consultants who serve them need to understand both the science and the business implications of those constraints.
Regulatory Strategy and Drug Approval
One of the highest-stakes areas in life science consulting is regulatory affairs. Getting a drug or biologic through the approval process requires navigating a series of formal interactions with agencies like the FDA, and each stage has specific submission requirements. Consultants help companies prepare for formal FDA meetings (pre-investigational drug application meetings, end-of-phase-2 meetings, pre-approval meetings) by authoring briefing packages, developing regulatory strategy documents, and conducting gap analyses to identify weaknesses before regulators find them.
Beyond meetings, consultants often handle the actual authoring and publishing of major regulatory submissions, including investigational new drug applications, biologics license applications, and new drug applications. They also support ongoing compliance work like annual safety reports and protocol amendments. For companies developing gene therapies, combination products, or other novel formats, regulatory consulting is especially critical because the approval pathways are less established and carry more uncertainty.
Pricing, Market Access, and Reimbursement
A drug that wins regulatory approval but can’t get covered by insurance or priced sustainably will fail commercially. This is where pricing and market access consulting comes in. Consultants work with companies at every development stage to build pricing strategies that account for the competitive landscape, payer expectations, and health technology assessment (HTA) requirements that vary by country and region.
This work involves answering layered questions: What price can the market sustain? How will different payers respond? What clinical evidence will health systems require before agreeing to cover the product? Consultants help companies identify the highest-impact reimbursement pathways, build evidence packages that align with what payers want to see, and develop contracting strategies for entering highly competitive markets. For global launches, this means coordinating pricing decisions across countries where one market’s price can influence another’s, a problem unique to pharmaceuticals.
Commercial Launch and Sales Strategy
Bringing a product to market requires a coordinated commercial effort that consultants often help design. This includes building a brand messaging framework, developing resources for payer teams and sales representatives, planning sales force deployment, and orchestrating the marketing campaign rollout alongside product distribution to pharmacies and hospitals.
Once a product is on the market, the work continues. Payer teams engage health plans and health systems. Sales and medical affairs teams communicate with healthcare professionals about the product’s clinical impact. Consultants help companies capture real-world evidence after launch, which can be used to refine messaging, address unmet needs in specific patient populations, and strengthen the product’s positioning against competitors over time.
Pipeline Evaluation and M&A Due Diligence
Life science companies regularly face decisions about which programs to fund, which to shelve, and which companies to acquire. Consultants play a central role in these portfolio decisions. Analysis from L.E.K. Consulting highlights two characteristics that consistently predict whether an acquired drug asset will meet commercial expectations: strategic positioning as a first-line therapy (used early in a patient’s treatment) and novelty of the drug’s mechanism. Assets that are first in their class tend to outperform, while “me-too” drugs entering saturated markets frequently disappoint.
There’s also a strong home-field advantage. About 50% of acquired assets within a company’s existing therapeutic focus meet or exceed pre-deal projections. When companies acquire assets outside their core areas, 63% fall short. Consultants use these kinds of benchmarks alongside competitive analysis, pricing forecasts, and clinical risk assessments to help executives decide which deals to pursue and how much to pay. The due diligence process itself requires integrating regulatory compliance review, product liability analysis, and data integrity checks into a single coherent picture of risk and value.
Digital Health and AI
A growing segment of life science consulting focuses on digital therapeutics and artificial intelligence. Digital therapeutics are FDA-cleared software platforms, sometimes paired with wearable devices, that treat chronic conditions through continuous monitoring and automated care management. Companies building these products face a unique set of challenges: they need expertise in product development, data science, regulatory clearance for software-as-a-medical-device, and strategic partnerships with healthcare systems. McKinsey estimates that healthcare incumbents should plan to spend three to five years building the digital capabilities needed to compete in this space.
AI and machine learning are also reshaping drug discovery and development. Predictive protein folding models can identify promising drug candidates faster than traditional lab methods, potentially saving years of work. The “Lab in a Loop” concept trains AI systems on data from laboratory and clinical studies, then uses those models to predict disease targets and therapeutic candidates that are validated back in the physical lab. Consultants help life science companies figure out where to integrate these technologies, how to scale them while meeting regulatory manufacturing standards, and how to shift from document-based to data-centric validation processes.
Who Works in Life Science Consulting
Life science consulting attracts people with advanced scientific training. PhDs, MDs, and PharmDs are common, often combined with MBAs or other business credentials. The field values people who can translate between the language of bench science and the language of business strategy. Many consultants come from research backgrounds in biology, chemistry, pharmacology, or medicine and transition into advisory roles where their technical depth gives them credibility with clients developing complex therapies.
The career path can also be a launching pad. Alumni of major consulting firms with life science backgrounds have gone on to become senior executives at pharmaceutical companies, biomedical research organizations, and healthcare-focused investment firms including private equity and venture capital funds.
Who Provides These Services
The life science consulting landscape includes both large generalist firms and specialized boutiques. Among the major firms, McKinsey, Boston Consulting Group, and Bain (the “Big Three” strategy firms) consistently rank at the top for health sciences work. The Big Four accounting firms, Deloitte, EY, PwC, and KPMG, also have significant life sciences consulting practices. On the boutique side, firms like ClearView Healthcare Partners, Trinity Life Sciences, and L.E.K. Consulting focus exclusively or heavily on life sciences, offering deep domain expertise and often more hands-on engagement models. The choice between a generalist and a boutique firm typically depends on the scope of the problem: a company rethinking its entire corporate strategy might turn to McKinsey, while one needing a detailed pricing and access strategy for a single product launch might prefer a specialist.